Iqvia Shares Climb After Tightening of 2025 Guidance Ranges

Dow Jones

Jul 22, 2025

By Rob Curran

Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts.

The Durham, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77.

Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months.

Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street target of $11.83 a share.

Iqvia is now targeting 2025 revenue between $16.1 billion and $16.3 billion, compared with a previous estimate of $16 billion to $16.4 billion and an average analyst estimate of $16.06 billion, as tallied by FactSet.

Shares of Iqvia rallied 8.2% to $172 premarket. At Monday's close, shares were down by roughly 35% from 12 months ago.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

July 22, 2025 08:30 ET (12:30 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2553525644"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553525644\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553525644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553525644","market":"hk","top_or_hot":-1,"title":"Iqvia Shares Climb After Tightening of 2025 Guidance Ranges","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts. \n</p>\n<p>\n  The Durham, N<a href=\"https://laohu8.com/S/02403\">.C</a>., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77. \n</p>\n<p>\n  Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months. \n</p>\n<p>\n  Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street target of $11.83 a share. \n</p>\n<p>\n  Iqvia is now targeting 2025 revenue between $16.1 billion and $16.3 billion, compared with a previous estimate of $16 billion to $16.4 billion and an average analyst estimate of $16.06 billion, as tallied by FactSet. \n</p>\n<p>\n  Shares of Iqvia rallied 8.2% to $172 premarket. At Monday's close, shares were down by roughly 35% from 12 months ago. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iqvia Shares Climb After Tightening of 2025 Guidance Ranges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIqvia Shares Climb After Tightening of 2025 Guidance Ranges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-22 20:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts. \n</p>\n<p>\n  The Durham, N<a href=\"https://laohu8.com/S/02403\">.C</a>., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77. \n</p>\n<p>\n  Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months. \n</p>\n<p>\n  Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street target of $11.83 a share. \n</p>\n<p>\n  Iqvia is now targeting 2025 revenue between $16.1 billion and $16.3 billion, compared with a previous estimate of $16 billion to $16.4 billion and an average analyst estimate of $16.06 billion, as tallied by FactSet. \n</p>\n<p>\n  Shares of Iqvia rallied 8.2% to $172 premarket. At Monday's close, shares were down by roughly 35% from 12 months ago. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 08:30 ET (12:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0130103400.USD","symbol_name":"Natixis Harris Associates Global Equity RA USD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553525644","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553525644","pubTimestamp":1753187400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts.The Durham, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77.Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months.Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4585":"ETF&股票定投概念","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4530":"医药外包概念","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4588":"碎股","IQV":"艾昆纬","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4121":"生命科学工具和服务","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"收紧2025年指导范围后Iqvia股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Iqvia rallied premarket after the provider of healthcare technology and research services tightened the range for its annual earnings and revenue forecasts. \n\n\n  The Durham, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted earnings of $266 million, or $1.54 a share, down from $363 million, or $1.97 a share. Adjusted earnings came to $2.81 per share, topping the average Wall Street estimate of $2.77. \n\n\n  Revenue rose 5.3% to $4.02 billion, topping the average analyst forecast of $3.96 billion, according to FactSet. Research-and-development revenue ticked up 2.5% to $2.2 billion. The backlog at its research-and-development unit also rose 5.1% to $32.1 billion, and the company expects $8.1 billion of that to be recognized as revenue in the next 12 months. \n\n\n  Iqvia forecast 2025 adjusted earnings in a range between $11.75 and $12.05 a share, compared with a previous estimate between $11.70 and $12.10 a share, and in line with the Wall Street target of $11.83 a share. \n\n\n  Iqvia is now targeting 2025 revenue between $16.1 billion and $16.3 billion, compared with a previous estimate of $16 billion to $16.4 billion and an average analyst estimate of $16.06 billion, as tallied by FactSet. \n\n\n  Shares of Iqvia rallied 8.2% to $172 premarket. At Monday's close, shares were down by roughly 35% from 12 months ago. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 22, 2025 08:30 ET (12:30 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}